News

Advancements in therapeutic agents demand innovative strategies for safe, localized skin treatments, Mitragotri argues.

Patients saw an average clearance rate of 74.46% after just 1 session of laser therapy.

Rezpegaldesleukin, a novel IL-2 receptor agonist, enters phase 2b evaluation for atopic dermatitis, aiming to advance therapeutic options for this chronic condition.

Post treatment discontinuation, most centers conduct imaging every 3 months during the first year of remission.

Chronic hand eczema poses diagnostic and treatment challenges due to its multifaceted etiology. New therapies like JAK inhibitors offer hope.

The recommendations place an emphasis on the utility of ultrasound-guided placement to enhance safety.

A study revealed ruxolitinib cream's rapid, lasting benefits in pediatric eczema without systemic safety concerns over a 52-week trial period.

The 5% dosage showed a 6-fold increase in non-vellus hair count after just 5 weeks.

DFD-29, FDA-approved in 2024, revolutionizes rosacea management by addressing both erythema and inflammatory lesions with a novel extended-release formulation.

A recent systemic review found FRM to be an effective treatment modality on its own for managing facial acne scars.

Mitragotri said new innovations like ionic liquid-based delivery systems can offer better treatment for immunodermatological conditions.

UVF dermoscopy enhances scabies detection, especially in dark skin, with optimal results when combined with polarized light examination.

The company is currently recruiting participants to demonstrate the benefits of its BioREtain technology.

Designed to mimic natural tissue scaffolds, DermiSphere hDRT offers innovative support for cellular infiltration and healing in reconstructive surgery.

The innovative technology is unlocking new possibilities in dermatology by improving the solubility and permeability of drugs for topical use.

The synergistic approach reduced submental fullness, enhanced mandible line definition, and improved chin projection.

Palvella begins its phase 2 TOIVA trial of Qtorin rapamycin gel for cutaneous venous malformations, targeting the mTOR pathway.

Experts explore innovative therapies, psychosocial impacts, and education strategies for managing atopic dermatitis in a Dermatology Times video series.

A Finnish review highlights imprecise use of L23.8 and L23.9 codes for allergic contact dermatitis.

While zinc deficiency shows strong ties to SD, researchers stated vitamin D's role is less clear and may depend on genetic factors.

The stable preparation combined vitamin C and hyaluronic acid with complexed ubiquinone in this initial study.

Explore systemic psoriasis management, covering obesity, depression, biologics, and innovative treatment approaches.

By addressing skin health proactively, runners can enhance performance and longevity in the sport while minimizing discomfort and long-term dermatological damage.

With further research, plants such as licorice, tomato, and parsley, could eventually be promising alternatives for melasma patients.

Christopher Bunick, MD, PhD, is an associate professor of dermatology and physician-scientist at Yale School of Medicine in New Haven, Connecticut.

The HA filler with tri-hyal technology reduced wrinkles on the forehead, upper lip, cheek folds, and crow’s feet for up to 18 months.

Share your insights and anticipation with us.

Repibresib’s localized delivery minimizes systemic exposure while targeting inflammatory pathways, a novel approach for vitiligo management.

The results showed promising improvements in all endpoints with high patient satisfaction and no safety concerns.

More improved skin hydration and barrier function was observed in moisturizers with anti-inflammatory ingredients, compared to those without.